# A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Study · id `cardio:ct-nct04576988` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04576988](<https://clinicaltrials.gov/study/NCT04576988>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04576988

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

## Technical summary

Registry record NCT04576988. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-25 (actual); primary completion 2022-08-26 (actual). Results posted on 2023-08-23.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 324 participants (enrolled count; ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Started: 2021-01-25 (actual) (ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Primary completion: 2022-08-26 (actual) (ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Completion: 2022-12-06 (actual) (ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Results first posted: 2023-08-23 (ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Canada; Czechia; France; Germany; Israel; Italy; Mexico; Netherlands; New Zealand; Poland; Serbia; South Korea; Spain; Sweden; Switzerland; United Kingdom (ClinicalTrials.gov record NCT04576988, source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04576988-2024-09-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)
- Condition: Pulmonary Arterial Hypertension
- Intervention (Biological): Sotatercept
- Intervention (Drug): Placebo
- Intervention (Drug): Background PAH Therapy
- Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (`cardio:org-acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-341e98`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension (`cardio:pubmed-36877098`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f684fb72643c132bb6442306875043701ee33f233b51bef012199e3a5bf85eef
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
